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In search of more efficacious and safe pharmacological treatments for atrial fibrillation
(AF), atria-selective antiarrhythmic agents have been promoted that target ion channels
principally expressed in the atria. This concept allows one to engage antiarrhythmic
effects in atria, but spares the ventricles from potentially proarrhythmic side effects. It
has been suggested that cardiac small conductance Ca2+-activated K+ (SK) channels
may represent an atria-selective target in mammals including humans. However, there
are conflicting data concerning the expression of SK channels in different stages
of AF, and recent findings suggest that SK channels are upregulated in ventricular
myocardium when patients develop heart failure. To address this issue, RNA-sequencing
was performed to compare expression levels of three SK channels (KCNN1, KCNN2,
and KCNN3) in human atrial and ventricular tissue samples from transplant donor hearts
(no cardiac disease), and patients with cardiac disease in sinus rhythm or with AF. In
addition, for control purposes expression levels of several genes known to be either
chamber-selective or differentially expressed in AF and heart failure were determined.
In atria, as compared to ventricle from transplant donor hearts, we confirmed higher
expression of KCNN1 and KCNA5, and lower expression of KCNJ2, whereas KCNN2
and KCNN3 were statistically not differentially expressed. Overall expression of KCNN1
was low compared to KCNN2 and KCNN3. Comparing atrial tissue from patients with
AF to sinus rhythm samples we saw downregulation of KCNN2 in AF, as previously
reported. When comparing ventricular tissue from heart failure patients to non-diseased
samples, we found significantly increased ventricular expression of KCNN3 in heart
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failure, as previously published. The other channels showed no significant difference in
expression in either disease. Our results add weight to the view that SK channels are not
likely to be an atria-selective target, especially in failing human hearts, and modulators
of these channels may prove to have less utility in treating AF than hoped. Whether
targeting SK1 holds potential remains to be elucidated.
Keywords: RNA-seq, SK channels, AF marker genes, atria-selective drugs, atrial fibrillation
INTRODUCTION
Treatment of atrial fibrillation (AF) with antiarrhythmic drugs is
hampered by the propensity of pharmacological interventions to
induce ventricular proarrhythmic effects. Attempts to circumvent
this problem have led to the concept of atria-selective drugs
that target ion channels expressed only or predominantly in the
atria, but not in the ventricles (for recent review see Peyronnet
and Ravens, 2019). Presently, four groups of ion channels are
considered to be atria-selective, i.e., the ultra-rapidly activating,
outward rectifier K+ channel, Kv1.5 (IKur) (Ravens and Wettwer,
2011), the acetylcholine-activated inward rectifier K+ channel,
Kir2.x (IK,ACh) (Koumi and Wasserstrom, 1994), the two-pore
domain K+ (K2P) channels, TWIK-1 (tandem of two-pore-
domain, weak inward rectifying K+-1) channel and TASK-1
(TWIK-related acid-sensitive K+) channel (Gaborit et al., 2007;
Schmidt et al., 2015), as well as the small conductance Ca2+-
activated K+ (SK) channels, SK1, SK2, and SK3 (Skibsbye et al.,
2014). Novel drugs that selectively target each group of these
ion channels have been associated with great expectations for
a breakthrough in pharmacological therapy of AF. However,
the results of clinical trials related to IKur and IK,ACh inhibitors
have been disappointing, due to lack of efficacy or on-target
toxicity (Pavri et al., 2012; Walfridsson et al., 2015; Podd et al.,
2016; Shunmugam et al., 2018). A clinical trial regarding the
efficacy and safety of a (non-selective) TASK-1 channel inhibitor
is still ongoing [Doxapram conversion to sinus rhythm (SR)
“DOCTOS” study, EudraCT No: 2018-002979-17, Protocol-
Code: K620]. For SK-channel inhibition, preclinical research is
ongoing (Saljic et al., 2019; Shamsaldeen et al., 2019; Diness
et al., 2020), and this atria-selective antiarrhythmic drug target
appears to be the only one not yet investigated in patients
(Heijman and Dobrev, 2017).
Apamin, a polypeptide bee venom toxin has been shown
to selectively inhibit SK channel current in mouse atrial and
ventricular myocytes, as well as in human atrial myocytes (Xu
et al., 2003). In addition, apamin prolongs action potential (AP)
duration to a much larger extent in atrial than in ventricular
Abbreviations: AF, Atrial fibrillation; AP, Action potential; Ca2+, Calcium;
CAD, Coronary artery disease; CVBB, Cardiovascular biobank; DCM, Dilated
cardiomyopathy; GIRK, G protein-coupled inwardly rectifying K+ channel; HF,
Heart failure; HVD, Heart valve disease; ICM, Ischemic cardiomyopathy; K+,
Potassium; K2P channels, Two-pore-domain K+ channels; LA, Left atrium; LV,
Left ventricle; mRNA, Messenger RNA; Na+, Sodium; PCA, Principal component
analysis; RAA, Right atrial appendage; RNA, Ribonucleic acid; RNA-seq, RNA-
sequencing; SD, Standard deviation; SK channel, Ca2+-activated K+ channel
of small conductance; SR, Sinus rhythm; TASK-1 channel, TWIK-related acid-
sensitive K+ channel 1; TPM, Transcripts per kilobase million; TWIK channels,
Tandem of two-pore-domain, weak inward rectifying K+ channels.
murine and human myocytes. In these cells, the atria-selective
expression of SK2 channels has been confirmed by Western
blot and polymerase chain reaction (Xu et al., 2003; Tuteja
et al., 2005). Interestingly, already the first description of cardiac
SK channels closes with suggesting them as putative target for
treating atrial arrhythmias (Xu et al., 2003). However, results
from subsequent work are conflicting. Genetic knock-out of the
SK2 channel gene in mice leads to marked atrial AP prolongation
with no change in ventricle, but knock-out animals exhibit
increased susceptibility to AF (Li et al., 2009). Nagy and co-
workers could not detect any effect of apamin on either atrial
or ventricular AP duration in rat, dog and human, though
determination in human atrial tissue was not carried out (Nagy
et al., 2009). Importantly, SK channels can form heteromers from
which some were reported to be apamin-insensitive, yet sensitive
to small molecule inhibitors such as UCL1684 (Hancock et al.,
2015; Shamsaldeen et al., 2019), a feature which may explain some
apparent discrepancies between studies. Experimental evidence
for the involvement of SK channels in electrical remodeling
during AF is also equivocal. In human atrial tissue, upregulation
(Zhou et al., 2014) or downregulation (Yu et al., 2012; Ling
et al., 2013; Skibsbye et al., 2014) of SK channel expression and
apamin-sensitive currents in AF have been reported.
The situation becomes even more unclear when recent
experimental evidence in animal and human cardiac tissue is
taken into account, which suggests that atria-selectivity of SK
channel inhibitors could be compromised in certain clinical
conditions (Chua et al., 2011; Chang et al., 2013a,b; Hsueh et al.,
2013; Bonilla et al., 2014). For example, ventricular expression of
SK2 channels is increased in a rat model of cardiac hypertrophy
due to thoracic aortic banding (Hamilton et al., 2020).
Given that AF and heart failure (HF) have been shown
to be pathological partners (Santhanakrishnan et al., 2016),
expression of SK channels in atrial and left ventricular (LV)
tissue from donor hearts not suitable for transplantation (no
structural cardiac disease) was compared to expression of SK
channels in LV tissue from patients with HF due to ischemic
(ICM) or dilated cardiomyopathy (DCM), who required a LV
assist device. In addition, expression of the SK channels was
studied in human atrial tissue from patients with structural
cardiac disease with SR or sustained AF. Expression data
were analyzed using a next generation sequencing effort.
We confirmed atria-selective expression of Kv1.5, Kir3.1,
and SK1 channels but not of SK2 and SK3. Our results
suggest that SK channels are expressed both in atria and
ventricles, and hence should not be considered as an atria-
selective target overall.
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TABLE 1 | Patient characteristics of sequenced samples.
Tissue provenance Left ventricle Right atrial appendage Left atrium
Health status Non-diseased DCM ICM Non-diseased CAD HVD AF Non-diseased
Structural heart disease No Yes Yes No Yes Yes Yes No
Heart rhythm SR SR SR/AF (4/1) SR SR SR AF SR
Number of samples 8 5* 5 7 7* 5* 6 6
Sex (♂/♀) 4/4 5/0 5/0 4/3 7/0 5/0 6/0 3/3
Age (mean ± SEM) 59.9 ± 1.8 44.0 ± 4.0 57.4 ± 2.4 60.3 ± 2.0 66.6 ± 4.1 55.8 ± 8.3 67.5 ± 1.7 61.0 ± 2.0
DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; CAD, coronary artery disease; HVD, heart valve disease; SR, sinus rhythm; AF, atrial fibrillation; ∗ after
removing one patient, respectively, for the reasons outlined in the text; SEM, standard error of the mean.
MATERIALS AND METHODS
Human Heart Samples
Human atrial tissue samples were obtained from patients
with SR or AF, undergoing open heart surgery at the
University Heart Center Freiburg-Bad Krozingen or at the
Clinic for Cardiac Surgery, Heart Center Dresden. These
samples were processed via the CardioVascular BioBank
(CVBB) Freiburg im Breisgau, as approved by the Ethics
Committee of the University of Freiburg, Freiburg im Breisgau,
Germany (CVBB ethical approval reference 393/16; study
approval reference 10719) and the Ethics Committee of the
Medical Faculty of the Technical University Dresden, Dresden,
Germany (ethical approval No. 15.1/01031/006/2008 and No.
EK790799). LV tissue from patients with HF due to ICM
or DCM was provided by the Department of Cardiology,
University Hospital Heidelberg, Heidelberg, Germany. The
study protocol was approved by the Ethics Committee of
the Medical Faculty of Heidelberg University, Heidelberg,
Germany (S-017/2013). Atrial and LV myocardium from donor
hearts not suitable for transplantation was obtained from
the University of Szeged, Szeged, Hungary [Study approval
by the Medical Research Council Budapest, Scientific and
Research Ethics Committee, Budapest, Hungary No. 4991-
0/2010-1018EKU (339/PI/010)]. Hearts were not suitable for
transplantation because they could not have reached a recipient
in time or because no suitable recipient was found within
time. Written and informed consent was obtained from all
patients and the study was conducted in accordance with the
Declaration of Helsinki.
Atrial and LV myocardium from donor hearts was used
as control (no structural cardiac disease) and will be referred
to as non-diseased henceforth. Furthermore, one patient was
affected by both, coronary artery disease (CAD) and heart
valve disease (HVD) and this tissue sample was grouped under
both conditions. From another patient two tissue samples from
the right atrial appendage (RAA) were sequenced. In order
to stay consistent with the number of samples per patient
per sample provenance and based on the principal component
analysis (PCA) plot (not shown), one of those samples was
withdrawn from analysis (Supplementary Figure 1). According
to the guidelines of the European Society of Cardiology,
the American Heart Association, the American College of
Cardiology, and the Heart Rhythm Society (January et al., 2014;
Kirchhof et al., 2016), for AF, one can distinguish between
paroxysmal which is self-terminating or cardioverted within
7 days, and sustained AF which includes patients with persistent
(lasting > 7 days), long-standing persistent (lasting > 1 year,
therapeutically addressed), and permanent (lasting > 1 year, not
therapeutically addressed). This classification is widely accepted
both in clinical and research settings (Jahangir et al., 2007; Mittal,
2014). In this study, only tissue from patients with sustained
AF was included in the AF group. Of note, all patients with
AF also had CAD or HVD, i.e., a structural heart disease, as
reason for cardiac surgery. Patient characteristics are summarized
in Table 1.
Due to the limited availability of patient tissue samples, studies
on human tissue often compare samples form patients with AF
or HF to SR. In order to relate better our results to published
work, especially results of functional experiments, LV samples
with DCM and ICM were pooled as HF and samples from RAA
with CAD and HVD were pooled for patients with SR.
RNA-Sequencing
Total ribonucleic acid (RNA) was extracted from 5 to 15 mg
frozen tissue using the RNeasy Mini kit or the RNeasy Micro kit
from Qiagen (Germany) following the manufacturer’s protocols.
Samples were first reduced to powder using a Spectrum
Bessman pulverizer (Thermo Fisher Scientific, United States),
chilled in liquid nitrogen, and homogenized in RLT lysis
buffer using a TissueLyser LT (Qiagen) with 5 mm stainless
steel beads for 2 × 2 min cycles at 30 Hz. After proteinase
K treatment for 10 min at 55◦C, homogenates were cleared
by centrifugation at 10,000 × g for 3 min and loaded on
RNeasy Mini Spin Columns or RNeasy MinElute Spin Columns
(Qiagen). After on-column deoxyribonuclease treatment and
washing, RNA was eluted in 20–30 µL ribonuclease free water
and stored at −80◦C. In total, RNA was extracted from 40
tissue samples from 39 patients and from 25 tissue samples
from 9 donor hearts.
RNA samples were quantified using the Qubit HS RNA kit
(Thermo Fisher Scientific) with a Qubit 3.0 Fluorometer
(Thermo Fisher Scientific), following manufacturer’s
instructions. The integrity of the RNA was determined
for all samples using an Agilent Bioanalyzer 2100 (Agilent
Technologies, United States) with an Agilent RNA 6000 kit
(Agilent Technologies). RNA samples with a RNA integrity
number > 7.0 were considered intact and < 7.0 were considered
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degraded. Based on this, 14 samples were not sequenced
(Supplementary Figure 1), including 1x non-diseased (LV),
2x DCM (LV), 3x ICM (LV), 1x non-diseased (RAA), 1x CAD
(RAA), 1x CAD and HVD (RAA), 1x ICM (RAA), 2x AF (RAA),
2x non-diseased (LA).
Next generation sequencing libraries were prepared from
200 ng total RNA using the Truseq Stranded messenger RNA
(mRNA) kit from Illumina (United States) that includes polyA
purification. After quality controls, libraries were pooled in
equimolar manner and run on Hiseq 4000 (Illumina) using a
2× 150 base pairs mode (paired-end) to obtain at least 35 million
reads per library.
Sequencing Data Analysis
The RNA-sequencing (RNA-seq) data analysis was carried out
using Galaxy platform1 (Afgan et al., 2018), following guidelines
from the tutorial “Reference-based RNA-Seq data analysis”
(Batut et al., 2018, 2020). In short, quality control checks on
raw sequence data was performed using FastQC (Andrews,
2010) and MultiQC (Ewels et al., 2016), taking into account
the per base sequence quality (Phred score), per sequence
quality scores (Phred score), per base sequence content, per
sequence GC content, sequence duplication levels and over-
represented sequences. Then, Cutadapt (Marcel, 2011) was used
to remove adapter sequences. The splice-aware aligner STAR
(Dobin et al., 2012) was used to map the RNA-seq reads onto
the human reference genome (hg19). The mapping results were
visualized by the integrative genome viewer, IGV (Robinson
et al., 2011). Thereafter, the strandness of the RNA-seq data
(reads mapping to the forward or reverse DNA strand) was
estimated using Infer Experiment from the RSeQC (Wang et al.,
2012). Gene expression was measured by featureCounts (Liao
et al., 2013). At this step, one sample had to be removed
from the study due to assignment of only 41% of the reads
(Supplementary Figure 1). To compare between samples, gene
counts were normalized for sequencing depth and gene length
using transcripts per kilobase million (TPM) (Li and Dewey,
2011). The PCA of gene expression was performed using DESeq2
R package (Love et al., 2014).
Statistical Analysis
Unless otherwise indicated, values are expressed as
mean ± standard deviation (SD). N-numbers refer to the
number of tissue samples, i.e., number of patients. Significance
of the difference between means was assessed using the
non-parametric Kruskal–Wallis test and Dunn’s test for
post-hoc analysis. When pooling conditions into HF and
SR, significance of the difference between means was tested
with the non-parametric Mann–Whitney test. Figure 1
illustrates the comparisons of interest. A p-value < 0.05 was
taken to indicate a significant difference between means.





AGTR1 Angiotensin II receptor type 1 or AT1 receptor
CACNA1C Ca2+ channel, voltage-dependent, L-type, α1G
subunit or Cav1.2
CACNA1D Ca2+ channel, voltage-dependent, L-type, α1G
subunit or Cav1.3






HPRT1 Hypoxanthine guanine phosphoribosyl
transferase 1
KCNA5 Kv1.5 or IKur channel or ultra-rapidly activating,
outward rectifier K+ channel
KCND3 Kv4.3 or K+ voltage-gated channel subfamily D
member 3
KCNJ2 Kir2.1 or K+ voltage-gated channel subfamily J
member 2
KCNJ3 GIRK1 or Kir3.1 or K+ inwardly rectifying
channel subfamily J member 3
KCNJ5 GIRK4 or Kir3.4 or K+ inwardly rectifying
channel subfamily J member 5
KCNK3 TASK-1 or TWIK-related acid-sensitive K+
channel 1
KCNN1-3 SK 1-3 or small conductance, Ca2+-activated K+
channel 1-3
MYH6/7 Myosin heavy chain 6/7
NPPA Atrial natriuretic peptide
PITX2 Paired-like homeodomain transcription factor 2
or pituitary homeobox 2
PPIA Peptidylprolyl isomerase A
SLC8A1 NCX1 or Na+/Ca2+ exchanger
Sample Characteristics
The PCA shows that the first dimension (PC1) roughly separated
samples originating from LV from those originating from atria,
and the second dimension (PC2) roughly separated samples
originating from diseased hearts from those originating from
non-diseased hearts (Figure 2). Differential gene expression
between atria and LV accounted for 45% of the variability
between individual samples, whereas disease-associated
differences in gene expression account for 11% of variability. One
data point (indicated by ∗) corresponded to a patient with CAD
and clustered within the non-diseased group. Because of this
discrepancy between clinical and experimental data, we decided
to exclude this from subsequent analysis (Supplementary
Figure 1). One patient was affected by both, CAD and HVD. The
PCA plot showed that this data point lied within the clusters of
these biological conditions and was retained for analysis.
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FIGURE 1 | Template figure for presentation of mRNA expression assessed
by RNA-seq. Some p-values will be indicated in all graphs (p-value), whereas
others are only indicated when p < 0.05 (only p < 0.05). Sample provenance:
left ventricle (LV), right atrial appendage (RAA), left atrium (LA). Patient’s health
status: non-diseased (ND); heart failure (HF; blue) summarizing data from
dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM); sinus
rhythm (SR; red) summarizing data from coronary artery disease (CAD) and
heart valve disease (HVD); atrial fibrillation (AF). Statistical significance was
assessed by Dunn’s test. For HF and SR, statistical significance was assessed
by the Mann–Whitney test.
We analyzed the expression of three housekeeping genes as
internal controls. Housekeeping genes are defined as genes with a
constant expression throughout chambers and throughout health
status. We selected the popular GAPDH (Molina et al., 2018),
PPIA (Molina et al., 2018), and HPRT1 (Cabiati et al., 2012).
All three housekeeping genes showed stable mRNA expression
between and within heart chambers, indicating a good quality of
samples and sequencing (Supplementary Figures 2A–C). Each
of these housekeeping genes covered a distinct range of TPM:
four-digit range for GAPDH, three-digit range for PPIA, and
one-digit range for HPRT1.
Chamber-Selective mRNA Expression
and Modulation Associated With Cardiac
Disease
The two isoforms of myosin heavy chain (MHC-α and
MHC-β) are encoded by the MYH6 and MYH7 genes,
respectively. Expression of MYH6 was dominant in atria, whereas
expression of MYH7 was dominant in the LV, confirming the
respective atria- and LV-selective expression of these two genes
(Figures 3A,B). Interestingly, in atrial samples from patients
with AF, MYH7 expression was significantly higher than in atrial
samples from patients with SR. To validate chamber-selective
expression of ion channels, we analyzed the mRNA expression
levels of KCNA5 (encoding Kv1.5), KCNJ2 (encoding the inward
rectifier K+ channel Kir2.1), as well as KCNJ3 and KCNJ5
(encoding the G-protein-activated inward rectifier K+ channels
Kir3.1 or GIRK1, and Kir3.4 or GIRK4, respectively). Expression
of KCNA5 in the LV was low, whereas it was significantly
higher RAA tissue, and no differences between non-diseased
and diseased heart tissue were detected, neither in atrial nor LV
samples (Figure 3C). Expression of the genes encoding inward
rectifier K+ channels is depicted in Figures 3D–F. For Kir2.1,
mRNA expression was significantly larger in the LV than in RAA
or left atrium (LA), and neither HF nor AF significantly changed
the expression level in LV or atria, respectively (Figure 3D).
In contrast, expression of KCNJ3 was significantly higher in
RAA and LA than in LV tissue and also higher in HF tissue
than in non-diseased LV tissue (Figure 3E). Expression of
KCNJ5, however, was not significantly different between LV and
atrial tissue. In addition, atrial expression of KCNJ5 was not
statistically different between samples from patients with SR and
AF but compared with RAA non-diseased samples (and also
when compared to all RAA samples from patients with SR),
KCNJ5 expression was significantly lower (Figure 3F). These
findings by-and-large confirm the atria-selective expression of
some characteristic genes.
Furthermore, we show genes encoding for ion channels
or exchangers for which HF- or AF-associated modulation of
expression has been reported previously (Figure 4). KCND3
contributes to the transient outward K+ current, Ito, via Kv4.3
channels (Figure 4A). Expression of KCND3 was not statistically
different in LV and atria but was lower in LV samples from failing
than from non-diseased hearts. KCNK3 encodes the background
K+ channel TASK-1 or K2P3.1. In contrast to KCND3, KCNK3
was expressed to a larger extent in LA than LV non-diseased
samples and was upregulated in AF (Figure 4B). Cardiac
L-type Ca2+ channel (Cav1.2 and Cav1.3) genes CACNA1C and
CACNA1D were more extensively expressed in RAA and LA
than in the LV, respectively (Figures 4C,D). For CACNA1C, no
difference was found between non-diseased and diseased tissue
samples, whereas CACNA1D was downregulated in HF and AF.
Expression of the T-type Ca2+ channel (Cav3.1) gene CACNA1G
was higher in RAA and LA than LV non-diseased samples.
The low expression of CACNA1G in the LV tissue from non-
diseased hearts was upregulated in HF samples (Figure 4E). The
Na+/Ca2+ exchanger encoded by SLC8A1 was statistically not
differentially expressed in LV and atrial tissue, but upregulated
in AF (Figure 4F).
In addition to the above described genes related to ion
transport, we also compared the expression of some disease-
associated genes (Figure 5). The atrial natriuretic peptide
encoding gene NPPA was highly abundant in RAA and LA
compared to LV. In addition, it was upregulated in both HF and
AF (Figure 5A). The angiotensin II receptor type 1 (AGTR1) gene
was more prominently expressed in RAA than LV non-diseased
tissue and when the LV was failing, AGTR1 expression was
significantly lower than in non-diseased LV tissue (Figure 5B). As
expected, expression of ventricular connexin-43 encoding gene
GJA1 was more prominent in LV than RAA, whereas the atrial
connexin-40 encoding gene GJA5 was more prominent in RAA
(Figures 5C,D). No disease-related modulation of expression
was detected in either gene. Another gene whose expression
was not statistically different between all conditions was CAV1
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FIGURE 2 | PCA plot illustrating inter- and intra-group variability of samples assessed by RNA-seq. Each individual point represents data from one tissue sample.
Dashed circles highlight clusters. ∗ indicates a data point showing discrepancy between clinical and experimental data. Sample provenance: left ventricle (LV; •), right
atrial appendage (RAA; N), left atrium (LA; H). Patient’s health status: non-diseased (ND; green, open symbols), dilated cardiomyopathy (DCM; light blue), ischemic
cardiomyopathy (ICM; blue), coronary artery disease (CAD; ocher), heart valve disease (HVD; orange), atrial fibrillation (AF; red).
(Figure 5E). CAV1 encodes for the protein caveolin-1 which is
required for forming specialized plasmalemmal invaginations,
recruiting and stabilizing large protein complexes involved in
signal transduction. The mRNA for transcription factor Pitx2
(paired-like homeodomain transcription factor 2), which is
responsible for the development of cardiac left-right asymmetry,
was massively expressed in LA non-diseased tissue (Figure 5F).
Chamber-Selective and Disease-Related
mRNA Expression of SK Channels
The genes described so far were selected because of their
previously reported chamber-selective expression or because
of known modulation of expression in HF or AF. Since the
main aim of this study was (i) to confirm chamber-selective
expression of SK channels and (ii) to comment on the therapeutic
potential of these channels in pharmacological treatment of AF,
we have analyzed the expression levels of three SK channels
encoded by KCNN1, KCNN2, and KCNN3 in our set of human
cardiac tissue samples (Figure 6). For KCNN1, significantly lower
mRNA expression was found in non-diseased LV than in non-
diseased RAA and LA (Figure 6A), whereas KCNN2 and KCNN3
(Figures 6C,E) showed no chamber-selective mRNA expression.
These results put into question the assumed atria-selective
expression of SK channels in general. In order to answer
the question of changes of ventricular SK channel expression
in association with HF, and of atrial SK channel expression
in association with AF, we also compared non-diseased LV
tissue to all samples from failing hearts, and all diseased RAA
samples from patients with SR to RAA tissue from AF patients.
Interestingly, of the SK channels, only LV expression of KCNN3
was higher in HF, whereas KCNN1 and KCNN2 were statistically
not differentially expressed. When comparing AF vs. SR tissue
samples, KCNN1 and KCNN3 were not statistically different
(Figures 6B,F), while KCNN2 was downregulated (Figure 6D).
DISCUSSION
In the present study using next generation sequencing, gene
expression in three types of human LV and five types of
atrial tissue samples was determined. Our main results are: (i)
principal component analysis yields clear clustering of atrial
vs. LV samples, and of diseased vs. non-diseased myocardium;
(ii) in non-diseased hearts, only SK1 (but not SK2 and SK3)
channels are expressed to a significantly larger extent in atrial
(RAA and LA) than in LV tissue samples; (iii) HF is associated
with an upregulation of SK3 channel, and AF is associated
with a downregulation of SK2 isoform. These findings will be
discussed below.
Sample Characteristics
The various myocardial samples had to be collected from
different hospitals, depending on tissue availability, but all
were processed in the same laboratory for RNA extraction and
preparation of the next generation sequencing libraries in order
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FIGURE 3 | Control of chamber identity and reproducibility of known chamber-selective gene expression in transcripts per kilobase million (TPM) assessed by
RNA-seq. (A) MYH6 (myosin heavy chain 6), (B) MYH7 (myosin heavy chain 7), (C) KCNA5 (Kv1.5 or IKur channel), (D) KCNJ2 (Kir2.1 or K+ voltage-gated channel
subfamily J member 2), (E) KCNJ3 (GIRK1 or Kir3.1 or K+ inwardly rectifying channel subfamily J member 3), (F) KCNJ5 (GIRK4 or Kir3.4 or K+ inwardly rectifying
channel subfamily J member 5). Sample provenance and patient’s health status as in Figure 2. Heart failure (HF): pooled data from DCM and ICM; sinus rhythm
(SR): pooled data from CAD and HVD. The mean ± SD data are represented. Statistical significance was assessed by Dunn’s test. For HF and SR, statistical
significance was assessed by the Mann–Whitney test.
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FIGURE 4 | Expression of ion channel encoding genes previously related to AF or HF in transcripts per kilobase million (TPM) assessed by RNA-seq. (A) KCND3
(Kv4.3), (B) KCNK3 (TASK-1 or TWIK-related acid-sensitive K+ channel 1), (C) CACNA1C (Cav1.2 or Ca2+ channel, voltage-dependent, L-type, a1C subunit), (D)
CACNA1D (Cav1.3 or Ca2+ channel, voltage-dependent, L-type, a1D subunit), (E) CACNA1G (Cav3.1 or Ca2+ channel, voltage-dependent, T-type, α1G subunit),
(F) SLC8A1 (NCX1). Same layout as in Figure 3.
to ensure best possible comparability. Despite the high number
of samples in which mRNA extraction was of insufficiently high
quality – in total, 14 samples had to be rejected – PCA for
all sixty thousand genes tested in the remaining 49 samples
yielded good clustering (Figure 2). Indeed, PCA demonstrated
four large clusters of data sets separating atrial from LV and
non-diseased from diseased heart samples. Only one data point
from RAA tissue from a CAD patient fell into the cluster for
non-diseased tissue and was discarded from further analysis. The
dimensions of the clusters demonstrate the scattering of the data
points within a biological condition which is inherently due to
inter-individual variability.
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FIGURE 5 | Control of disease identity and reproducibility of known AF- or HF-related gene expression in transcripts per kilobase million (TPM) assessed by
RNA-seq. (A) NPPA (atrial natriuretic peptide A), (B) AGTR1 (AT1 receptor or angiotensin II receptor type 1), (C) GJA1 (connexin-43), (D) GJA5 (connexin-40), (E)
CAV1 (caveolin-1), (F) PITX2 (paired-like homeodomain transcription factor 2). Same layout as in Figure 3.
Chamber-Selective mRNA Expression
and Modulation Associated With Cardiac
Disease
Given the large scatter in values within each sample
group, the expression of several additional genes of
known chamber-selective expression or previously
reported disease-associated modulation was determined
for control purposes. MYH6 and MYH7 encoding the
two MHC isoforms MHC-α and MHC-β were utilized
for validation of atria- or LV-selective gene expression
(Everett, 1986; Kurabayashi et al., 1988). In accordance
with the literature, expression of MYH6 was significantly
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FIGURE 6 | Assessment of chamber-selective and disease-related mRNA expression of SK channels in transcripts per kilobase million (TPM) assessed by RNA-seq.
(A) Expression of KCNN1 (SK1) in all sample groups; (B) Comparison of KCNN1 expression in LV tissue from non-diseased and failing hearts, in right atrial tissue
from SR and AF patients, and in non-diseased left atrial tissue from non-diseased hearts. (C,D) Expression of KCNN2 (SK2); (E,F) expression of KCNN3 (SK3),
figure lay-out as in (A,B). Sample provenance, patient’s health status and statistical tests as in Figure 3. Since disease-associated differences in expression of SK
channels were our main concern, we separately depicted the statistical comparisons for HF and AF (B,D,F).
higher in atrial than LV tissue, and the opposite was true for
MYH7 expression.
The cardiac K+ channel Kv1.5 is the best studied
representative of an atria-selective drug target based on
electrophysiological and mRNA expression data (Amos et al.,
1996; Gaborit et al., 2007). Numerous small molecule Kv1.5
inhibitors intended for treatment of AF have been developed
(Ford and Milnes, 2008). Our results confirm previously
published atria-selective expression of human KCNA5 and
lack of AF-associated remodeling of mRNA expression
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(Gaborit et al., 2007). Table 2 summarizes the results of all
genes that were tested for preferential expression in atria or LV
in comparison with the literature. For the vast majority of cases
we confirm the reported chamber-selective expression, although
in some cases we were not able to detect the reported differences.
However, this is not surprising, given the differences in patient
numbers and populations as well as the different experimental
conditions. Taken together, the chamber-selective expression
of control genes reported here is in good agreement with the
published literature (as summarized in Table 2) suggesting that
our RNA analysis is reliable.
Since the focus of this study was not only at chamber-selective
but also disease-modulated gene expression, some genes that are
known to be differentially expressed in HF or AF, as for instance
NPPA (Macchia, 1987), have been analyzed. We confirm that
expression of NPPA was dominant in non-diseased atria, but LV
TABLE 2 | Summary of differential gene expression for all genes in this study.
Gene RAA vs. LV LA vs. LV LV RAA
MYH6 ↑ (↑1,2) ↑ (↑1,2) ↓ (↓3) -
MYH7 ↓ (↓1,2) ↓ (↓1,2) - ↑ (↑4,5)
KCNA5 ↑ (↑6) - (↑6) - − (− or ↓6)
KCNJ2 ↓ (↓6) ↓ (↓6) - − (↑5,7,8)
KCNJ3 ↑ (↑6) ↑ (↑6) ↑ − (↓8,9)
KCNJ5 - - - − (↓7,9)
KCND3 - - ↓ − (↓8,9,10)
KCNK3 - ↑ - ↑ (↑11,12)
CACNA1C - ↓ - − (↓8,13)
CACNA1D ↑ - ↓ ↓ (↓8,13)
CACNA1G ↑ ↑ ↑ − (↓5,8)
SLC8A1 - - - ↑ (↑8,14)
NPPA ↑ (↑15) ↑ (↑15) ↑ (↑16,17,18) ↑ (↑19)
AGTR1 ↑ - ↓ − (↓5,20)
GJA1 ↓ - - − (− or ↑8,21)
GJA5 ↑ - - − (↓8,21)
CAV1 - - - − (↓22,23)
PITX2 - ↑ - − (↓24,25)
KCNN1 ↑ (↑26) ↑ - -
KCNN2 − (↑26) - − (↑27,28) ↓ (↓26)
KCNN3 − (↑26) - ↑ (↑29) − (↓26)
Upregulation (↑), downregulation (↓), or no significant difference (-) are indicated
such that the symbols outside parentheses sum up our experimental observations,
and the symbol within parentheses previously reported findings form the literature.
For 21 comparisons our observations match prior reports (green background).
In 17 cases, our data did not show statistically significant differences for
comparisons that had previously been reported to differ (orange background).
Sample provenance: left ventricle (LV), right atrial appendage (RAA), left atrium
(LA). Patient’s health status: non-diseased (ND); heart failure (HF): pooled data
from dilated cardiomyopathy and ischemic cardiomyopathy; sinus rhythm (SR):
pooled data from non-diseased, coronary artery disease and heart valve disease;
atrial fibrillation (AF). 1Everett, 1986; 2Kurabayashi et al., 1988; 3Miyata et al.,
2000; 4Nielsen et al., 2018; 5Thomas et al., 2019; 6Gaborit et al., 2007; 7Dobrev
et al., 2001; 8Gaborit et al., 2005; 9Brundel et al., 2001; 10Grammer et al., 2000;
11Schmidt et al., 2015; 12Schmidt et al., 2017; 13Van Wagoner and Nerbonne,
2000; 14Schotten et al., 2002; 15Macchia, 1987; 16Chien et al., 1991; 17Schmitt
et al., 2003; 18Houweling et al., 2005; 19Büttner et al., 2018; 20Goette et al., 2000;
21Nao et al., 2003; 22Yi et al., 2014; 23Martin et al., 2015; 24Chinchilla et al., 2011;
25Kirchhof et al., 2011; 26Skibsbye et al., 2014; 27Chang et al., 2013a; 28Hamilton
et al., 2020; 29Bonilla et al., 2014.
NPPA expression was activated in response to HF (Chien et al.,
1991; Schmitt et al., 2003; Houweling et al., 2005). Moreover,
NPPA expression was upregulated in RAA from patients with AF
(Büttner et al., 2018). In addition, we also found AF-associated
upregulation of MYH7 (Nielsen et al., 2018; Thomas et al., 2019),
KCNK3 (Schmidt et al., 2015, 2017), SLC8A1 (Schotten et al.,
2002; Gaborit et al., 2005), and downregulation of CACNA1D
(Van Wagoner and Nerbonne, 2000; Gaborit et al., 2005). For
the other genes, for which AF-induced expression changes have
been reported (see Table 2), we have not detected any significant
changes in expression between atrial samples from patients with
AF or SR. However, for two comparisons, part of the published
literature agrees with our inability to detect a difference. Not in a
single case did we observe statistically significant differences that
were in the opposite direction to previously published reports.
Failure to detect a significant difference does not indicate absence
of any difference, but could also imply that the number of
samples (in either of the analyzed cohorts) may not have been
large enough. Overall, the agreement of our expression profiles
with previous reports instills confidence that – where we do see
differences – we can draw reliable conclusions, such as about SK
channel expression in human atrial and LV myocardium.
Chamber-Selective and Disease-Related
mRNA Expression of SK Channels
The main purpose of our analysis was to assess whether SK
channels are expressed to a much larger extent in atria than
in the LV, which would presumably be necessary for them
to serve as atria-selective drug targets. The first detection of
SK channels in the heart demonstrated greater abundance
in atria than ventricles, although only in mouse and not
in human (Xu et al., 2003). Since then, evidence for atria-
selective expression of SK channels has been obtained for many
species (Tuteja et al., 2005: mouse; Diness et al., 2010: rat,
guinea pig, rabbit; Skibsbye et al., 2014: human). To the best
of our knowledge, our study is the first report of a direct
comparison of atrial and LV SK channel expression in human
non-diseased and diseased myocardium. We found a significantly
higher expression of KCNN1 in RAA and LA tissue than
in LV from non-diseased hearts, suggesting potential atria-
selectivity for the SK1 channel. However, despite substantial
expression of KCNN2 and KCNN3 in all chambers, these
genes were not significantly enriched in the atria (compared
to LV) in non-diseased hearts. Since non-diseased hearts do
not require therapy, and since atria-selective drugs are intended
for treatment of AF, we scrutinized SK channel expression in
atrial tissue from patients with AF in comparison to atrial
tissue from non-diseased donors or patients (CAD, HVD) with
SR. In accordance with previous findings for AF, expression
of KCNN1 did not significantly change and KCNN2 was
downregulated, whereas we did not observe the previously
reported downregulation of KCNN3 expression (Skibsbye et al.,
2014). The rationale for suppressing atrial arrhythmias with
SK channel blockers is to increase atrial refractoriness (Diness
et al., 2020). The observed downregulation of SK2 may be an
auto-regulatory mechanism which could be promoted by SK
channel inhibitors.
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Heart failure is a common comorbidity of AF and is associated
with remodeling of ion channel expression in the ventricles
(Nattel et al., 2007). Therefore, we also compared SK channel
expression in tissue from failing and non-diseased human hearts.
Of the three SK channels, KCNN3 was upregulated in failing
human LV, while the other two SK channels were not statistically
different. In the literature, SK channels in general were reported
as being upregulated in failing rabbit hearts (Chua et al., 2011),
SK2 channels in human failing (vs. non-failing) ventricular tissue
or hypertrophied mouse ventricles (Chang et al., 2013a; Hamilton
et al., 2020), and SK3 channels in failing dog hearts (Bonilla
et al., 2014). It is an ongoing debate of whether SK channel
upregulation is anti- or proarrhythmic (Chang and Chen, 2015;
Van Wagoner, 2015).
Of course, it is difficult to correlate mRNA expression and
protein function. For SK channels, this is further complicated
by the fact that most inhibitors or activators are not selective
for one of the three subtypes. For example, the most commonly
used SK channel inhibitor, apamin, shows only some selectivity
between SK channel subtypes, with SK2 being the most sensitive
(Weatherall et al., 2011). Furthermore, the physiological role
of SK channels in the heart is complex. There is evidence
suggesting that in human atrial myocytes, activation of SK2-
SK3-heteromers contributes to repolarization of the AP. These
SK2-SK3-heteromers are insensitive to apamin, but inhibited
by the small organic molecule inhibitor UCL1684 (Hancock
et al., 2015; Shamsaldeen et al., 2019). Therefore, one cannot
reliably extrapolate from observed mRNA levels to SK channel
subtype function.
In any case, though, upregulation of ventricular SK channels
such as SK2 and SK3 in HF, in the presence of unchanged or
downregulated expression in the atria, would suggest reduced
potential for atria-selectivity of pharmacological interventions.
Based on our mRNA expression data from human tissue
samples, only SK1 channels fulfilled the criteria for an atria-
selective drug target that is conserved in HF. However, the
contribution of SK1 channels to repolarization of the action
potential is not well established because functional data are
usually obtained with the SK channel inhibitor apamin – to
which SK1 channels are least sensitive (Grunnet et al., 2001). This
calls for further basic research, using SK1-targeting genetic or
pharmacological interventions, to fully evaluate its potential as
an atria-selective target.
Limitations
The number of biological replicates was low, due to the limited
quantity of patient material and the exclusion of several samples
with low RNA integrity numbers, however, it was ≥ 5 for
each sub-goup, which we regard as a lower limit. Higher
n-numbers would be needed to assess the question of whether the
here reported lack of statistically significant changes in certain
RNA levels previously reported to be up- or downregulated
(Table 2), offers a generalizable view of electrophysiological
remodeling in AF.
All diseased human hearts samples were from male patients
while non-diseased samples came in equal parts from male and
female individuals. This is due to the fact that the number of
patients was limited and we had to prioritize clinical entities,
rather than gender. For this reason, we cannot address sex-
specific differences in mRNA expression. Sex-related differences
in myocardial gene expression have been reported previously
(Guo et al., 2017; Inanloorahatloo et al., 2017), so this forms an
area for further research.
Right atrial appendage tissue from AF patients is compared
to tissue from patients with SR to describe changes in gene
expression in patients with AF. While RAA is the human atrial
tissue that is most frequently removed during open heart surgery
and therefore available for scientific investigation, analysis of
gene expression in the LA would be of even greater interest, as AF
is most is often associated with electrophysiological abnormalities
in LA and pulmonary veins (Haïssaguerre et al., 1998).
In the past, several groups have searched for altered ion
channel expression in human atrial tissue in order to explain the
typical changes in AP shapes (electrical remodeling) seen in AF
(Van Wagoner and Nerbonne, 2000; Dobrev and Ravens, 2003).
Changes in expression of mRNA do not necessarily manifest
themselves in matching changes in presence and activity of the
proteins they encode. A particular gene product may be further
modified during translational or even by post-translational
processes. Moreover, newly synthetized proteins such as ion
channels can remain trapped in the endoplasmic reticulum for
some time before they are recruited to their proper functional
compartment, the plasmalemma (Schumacher and Martens,
2010). Therefore, the here presented results do not provide
insight into the actual electrophysiological remodeling in AF.
CONCLUSION
In this study, we assess key genes with selective expression in
either atria or LV, and their up- or downregulation in AF or HF.
We document SK channel expression in atria and LV of hearts
from patients with or without structural cardiac disease. We
conclude that only SK1, but not SK2 and 3, shows a preferential
expression in the atria in non-diseased and diseased hearts, albeit
at low expression levels whose functional relevance remains to be
assessed. General blockers of SK channels are not likely to have
atria-selective effects, and hence may prove to have less utility in
treating AF than hoped.
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Supplementary Figure 1 | Flow chart illustrating the inclusion criteria. Number
(N◦) of human heart tissue samples entered, removed after assessment at different
quality control stages, and finally included in the analyses is shown. PCA, Principal
component analysis; TPM, transcripts per kilobase million.
Supplementary Figure 2 | mRNA expression of housekeeping genes in
transcripts per kilobase million (TPM) assessed by RNA-seq. (A) GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), (B) PPIA (peptidylprolyl-isomerase
A), and (C) HPRT1 (hypoxanthine-phosphoribosyltransferase 1). Sample
provenance: left ventricle (LV; •, right atrial appendage (RAA; N), left atrium (LA;
H). Patient’s health status: non-diseased (ND; green, open symbols); heart failure
(HF): pooled data from dilated cardiomyopathy (DCM; light blue) and ischemic
cardiomyopathy (ICM; blue); sinus rhythm (SR): pooled data from coronary artery
disease (CAD; ocher) and heart valve disease (HVD; orange); atrial fibrillation (AF;
red). The mean ± SD data are represented. Statistical significance was assessed
by Dunn’s test. For HF and SR, statistical significance was assessed by the
Mann–Whitney test.
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